NCT03064841 is a clinical trial of No Treatment in Type 2 Diabetes Mellitus, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT03064841?

NCT03064841 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT03064841?

Interventions in NCT03064841: No Treatment.

What condition does NCT03064841 study?

NCT03064841 studies Type 2 Diabetes Mellitus.

Is NCT03064841 still recruiting?

NCT03064841 is currently completed. Last updated 28 August 2019.

Are results published for NCT03064841?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-08-28 · How we verify

NCT03064841

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China

Completed Results posted Last updated 28 August 2019

What this trial tests

trial testing No Treatment in Type 2 Diabetes Mellitus in 1,537 participants. Completed in 30 December 2017.

Timeline

9 March 2017

Primary endpoint
30 December 2017

30 December 2017

Quick facts

Lead sponsor	Boehringer Ingelheim
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,537
Start date	9 March 2017
Primary completion	30 December 2017
Estimated completion	30 December 2017
Sites	18 locations across China

Drugs / interventions tested

No Treatment — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

60 and older, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) Guidelines. Primary · At study visit (one day)

The percentage of patients attaining blood glucose control target defined as HbA1c\<7%, according to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) guidelines.

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	43.4

Renal Function Level of Patients Measured by Albuminuria Secondary · At study visit (one day)

The renal function level of patients was measured by albuminuria into following categories - normal, micro-albuminuria, macro-albuminuria and missing data. Albuminuria was measured using either as a random spot urine sample, a 24-h urine sample, or a timed urine sample. Normal was defined as \< 30 mg/g, \<30 mg/24h, and \< 20 μg/min with the random spot urine sample, the 24-h urine sample, and the timed urine sample, respectively. Micro-albuminuria was defined as 30 - 300 mg/g, 30 - 300 mg/24h, and 20 - 200 μg/min with the random spot urine sample, the 24-h urine sample, and the timed urine s

Normal

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	63.8

Micro-albuminuria

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	27.6

Macro-albuminuria

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	7.1

Missing

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	1.5

Renal Function Level of Patients Measured by Estimated Glomerular Filtration Rate (eGFR) Secondary · At study visit (one day)

The renal function level of patients was measured by estimated glomerular filtration rate (eGFR).

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	85.019	± 18.204

Renal Function Level of Patients Measured by Chronic Kidney Disease (CKD) Stage Secondary · At study visit (one day)

The renal function level of patients was measured by CKD into following categories - eGFR ≥ 60 milliLitre/minute/1.73 meter \^ 2 (mL/min/1.73m\^2), eGFR \< 60 mL/min/1.73m\^2 and missing data.

eGFR >=60 mL/min/1.73m^2

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	51.1

eGFR < 60 mL/min/1.73m^2

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	5.4

Missing eGFR data

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	43.6

Treatment Regimens for T2DM That Patient Are Currently Taking Secondary · At study visit (one day)

The treatment regimens for T2DM that patient are currently taking.

No treatment

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	2.6

Only diet control and exercise

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	7.5

Oral antidiabetic drug (OAD) - Mono therapy

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	16.8

OAD - Combined therapy

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	28.7

Insulin only

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	15.5

OAD and Insulin

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	28.3

Missing

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	0.6

Percentage of Patients Macro-vascular and Micro-vascular Diabetic Complications Secondary · At study visit (one day)

The percentage of patients macro-vascular and micro-vascular diabetic complications.

Cardiovascular disease

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	14.9

Cerebrovascular disease

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	11.2

Peripheral vascular disease

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	8.8

Kidney disease

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	8.6

Retinopathy

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	14.4

Neuropathy

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	13.6

Percentage of Patients With Hypoglycaemic Occurrence Secondary · At study visit (one day)

The percentage of patients with hypoglycaemic occurrence.

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	28.0

Percentage of Patients With Hypoglycaemia Leading to Therapy Change Secondary · At study visit (one day)

The percentage of patients with hypoglycaemia leading to therapy change.

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	7.2

Percentage of Patients With Anti-hypertension Therapy Usage Secondary · At study visit (one day)

The percentage of patients with anti-hypertension therapy usage.

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	49.0

Percentage of Patients With Lipid Lowering Therapy Usage Secondary · At study visit (one day)

The percentage of patients with lipid lowering therapy usage.

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	29.2

Percentage of Patients With Anti-platelet Therapy Usage Secondary · At study visit (one day)

The percentage of patients with anti-platelet therapy usage.

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	30.1

Follow up Duration of Type 2 Diabetes Related Risk Factors in Clinical Practice Secondary · At study visit (one day)

The follow up duration of type 2 diabetes related risk factors was summarized using the situation of lab test including serum creatinine, uric acid, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride and total cholesterol.

Follow-up duration - within 3 months

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	33.6

Follow-up duration - within 3 to 6 months

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	16.1

Follow-up duration - within 6 to 12 months

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	17.3

Follow-up duration - More than 12 months

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	27.8

Missing follow-up duration

Group	Value	95% CI
Outpatients With Confirmed Type 2 Diabetes Mellitus (T2DM)	5.3

Sponsor's own description

This is a multi-centre, cross-sectional, non-interventional study assessing blood glucose target attainment, anti-hyperglycaemic treatment pattern and the clinical characteristics in older outpatients with Type 2 Diabetes Mellitus (T2DM) in hospitals of China. This study is designed to collect information of older T2DM patients in a real life setting

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No Treatment

Trials testing the same drug.

NCT07286487 — Glycyrrhetinic Acid and Acute Irritant Dermatitis · NA · not yet recruiting
NCT07268196 — Impact of Liver Transplantation on Sexual Life and Function · recruiting
NCT05938270 — A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly · Phase 1 · recruiting
NCT04858022 — Visual Acoustic Biofeedback for RSE Via Telepractice · Phase 2 · completed
NCT05987917 — Clinical and Histological Evaluation of BTL-785F Non-invasive Treatment for Facial Rejuvenation · NA · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03064841 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03064841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing